Evidence map›Paper›PMID 37340330›Full record

ArticleBMC neurology2023

Essential information for neurorecovery clinical trial design: trajectory of global disability in first 90 days post-stroke in patients discharged to acute rehabilitation facilities.

Shayandokht Taleb, Jenny Ji-Hyun Lee, Pamela Duncan, Steven C Cramer, Mersedeh Bahr-Hosseini, Michael Su, Sidney Starkman, Gilda Avila, Arielle Hochberg, Scott Hamilton and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMC neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Cost-effectiveness of the ABCStroke pathway in ischaemic stroke care: a UK pilot analysis.European heart journal. Quality of care & clinical outcomes · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Shayandokht TalebDepartment of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, USA. talebshayandokht@gmail.com.
Jenny Ji-Hyun LeeDepartment of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, USA.
Pamela DuncanDepartment of Neurology, Wake Forest School of Medicine, Winston-Salem, USA.
Steven C CramerDepartment of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, USA.
Mersedeh Bahr-HosseiniDepartment of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, USA.
Michael SuDepartment of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, USA.
Sidney StarkmanDepartments of Emergency Medicine and Neurology, David Geffen School of Medicine at UCLA, Los Angeles, USA.
Gilda AvilaDepartment of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, USA.
Arielle HochbergBrainQ Technologies Ltd, Jerusalem, Israel.
Scott HamiltonDepartment of Neurology, Stanford University, Stanford, USA.
Robin A ConwitNational Institute of Neurological Disorders and Stroke, Bethesda, USA.
Jeffrey L SaverDepartment of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, USA.
University of California, Los Angeles · USIsrael Brain Technologies · ILLos Angeles Medical Center · USNational Institute of Neurological Disorders and Stroke · USStanford University · USWake Forest University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMany stroke recovery interventions are most beneficial when started 2-14d post-stroke, a time when patients become eligible for inpatient rehabilitation facilities (IRF) and neuroplasticity is often at its peak. Clinical trials focused on recovery need to expand the time from this plasticity to later outcome timepoints.

methodsThe disability course of patients with acute ischemic stroke (AIS) and intracranial hemorrhage (ICH) enrolled in Field Administration of Stroke Therapy Magnesium (FAST-MAG) Trial with moderate-severe disability (modified Rankin Scale [mRS] 3-5) on post-stroke day4 who were discharged to IRF 2-14d post-stroke were analyzed.

resultsAmong 1422 patients, 446 (31.4%) were discharged to IRFs, including 23.6% within 2-14d and 7.8% beyond 14d. Patients with mRS 3-5 on day4 discharged to IRFs between 2-14d accounted for 21.7% (226/1041) of AIS patients and 28.9% (110/381) of ICH patients, (p < 0.001). Among these AIS patients, age was 69.8 (± 12.7), initial NIHSS median 8 (IQR 4-12), and day4 mRS = 3 in 16.4%, mRS = 4 in 50.0%, and mRS = 5 in 33.6%. Among these ICH patients, age was 62.4 (± 11.7), initial NIHSS median 9 (IQR 5-13), day 4 mRS = 3 in 9.4%, mRS = 4 in 45.3%, and mRS = 5 in 45.3% (p < 0.01 for AIS vs ICH). Between day4 to day90, mRS improved ≥ 1 levels in 72.6% of AIS patients vs 77.3% of ICH patients, p = 0.3. For AIS, mRS improved from mean 4.17 (± 0.7) to 2.84 (± 1.5); for ICH, mRS improved from mean 4.35 (± 0.7) to 2.75 (± 1.3). Patients discharged to IRF beyond day14 had less improvement on day90 mRS compared with patients discharged between 2-14d.

conclusionsIn this acute stroke cohort, nearly 1 in 4 patients with moderate-severe disability on post-stroke day4 were transferred to IRF within 2-14d post-stroke. ICH patients had nominally greater mean improvement on mRS day90 than AIS patients. This course delineation provides a roadmap for future rehabilitation intervention studies.

Indexed as

Brain IschemiaIschemic StrokeStrokeClinical Trials as TopicHumansIntracranial HemorrhagesPatient DischargeTreatment OutcomeCerebral IschemiaIntracerebral HemorrhageModified Rankin ScoreRehabilitationStrokeStroke Recovery

Identifiers

PMID37340330
PMCPMC10280859
OpenAlexW4381334816

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.